Brief: Galapagos NV Ends R&D Deal With Ryvu Therapeutics
April 6 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* NOTICE OF TERMINATION REGARDING OPTION, LICENSE AND
COLLABORATION AGREEMENT WITH GALAPAGOS NV
* FOLLOWING THIS DEAL TERMINATION, GRANTED LICENSE WILL
EXPIRE AMD
RYVU WILL GAIN FULL COPYRIGHT TO ALL MOLECULES AND KNOW-HOW
GIVEN TO GALAPAGOS
* COMPANY IS NOT OBLIGATED TO PAY ANY REMUNERATION OR TO
REFUND
ANY SUMS OBTAINED FROM GALAPAGOS UNDER PREVIOUSLY SIGNED DEAL
Source text for Eikon: ID:nEM6Xh3kBa
Further company coverage: RVU.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys